Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MKL001
- Development stage
- Preclinical
- Lead developer
- MiHKAL
- Modality
- Small Molecules
01
Overview
MKL001 is a preclinical-stage small molecule prodrug being developed by the Swiss pharmaceutical company MiHKAL GmbH for the treatment of Post-Traumatic Stress Disorder (PTSD). The drug is engineered to be enzymatically activated in human blood, employing a prodrug strategy similar to that of lisdexamfetamine (Vyvanse) to provide tunable release kinetics. This activation mechanism has been validated through in vitro digestion assays. While the specific active ingredient and its biological targets remain undisclosed, MKL001 represents one of the lead candidates in MiHKAL's pipeline focused on addressing the unmet needs of patients with PTSD.
Beyond the preview
Go deeper on MKL001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MKL001.